PUBLISHER: TechSci Research | PRODUCT CODE: 1692343
PUBLISHER: TechSci Research | PRODUCT CODE: 1692343
Stargardt Disease Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Distribution Channel, By Region & Competition, 2020-2030F
We offer 8 hour analyst time for an additional research. Please contact us for the details.
Global Stargardt Disease Therapeutics Market was valued at USD 202.75 million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.50% through 2030. In Stargardt disease, an inherited eye condition, the macula, which plays a crucial role in clear central vision, is adversely affected. This condition typically manifests in childhood or adolescence and gradually leads to a decline in visual acuity. While there are currently no approved treatments for Stargardt disease, significant progress has been made in the development of therapeutic approaches aimed at managing the condition and potentially arresting its progression. For instance, in 2023, WHO reported that over 2.2 billion people worldwide have vision impairment, with at least 1 billion cases preventable or unaddressed. The primary causes of blindness and vision loss globally are refractive errors and cataracts, highlighting the urgent need for improved eye care and preventive measures.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 202.75 Million |
| Market Size 2030 | USD 310.41 Million |
| CAGR 2025-2030 | 7.50% |
| Fastest Growing Segment | LBS-008 |
| Largest Market | North America |
Key Market Drivers
Increased Prevalence and Awareness
The prevalence of Stargardt Disease has been on the rise, with an increasing number of individuals being diagnosed with this condition worldwide. While it remains a rare disease, the broader global population and improved diagnostic capabilities have led to more cases being identified. This heightened prevalence underscores the urgency of finding effective treatments and therapies for those affected. For instance, in 2025, Ascidian Therapeutics has received FDA authorization to begin a Phase 1/2 clinical trial for ACDN-01, its RNA editing therapy for Stargardt disease, a genetic eye disorder caused by ABCA4 mutations. Unlike traditional gene therapies, ACDN-01 rewrites RNA exons to restore healthy protein production, potentially benefiting many affected individuals.
Stargardt Disease primarily affects children and young adults, but the ageing population has also contributed to its increasing prevalence. As the global population continues to age, the demand for treatments for age-related eye conditions, including Stargardt Disease, is expected to grow significantly. This demographic shift amplifies the market potential for Stargardt Disease therapeutics.
Key Market Challenges
Limited Understanding of the Disease Mechanism
Despite significant progress, our understanding of the exact mechanisms underlying Stargardt Disease remains incomplete. This knowledge gap can impede the development of targeted therapies and necessitates ongoing research to uncover the complexities of the condition.
Key Market Trends
Gene Therapy Breakthroughs
Gene therapy is emerging as a promising avenue in the quest to treat Stargardt Disease. Researchers are conducting clinical trials to test the safety and efficacy of gene therapies that aim to replace or correct the faulty genes responsible for the condition. As trials progress, breakthroughs that bring gene therapy closer to becoming a viable treatment option are likely to come up.
Key Market Players
- Kubota Pharmaceutical Holdings Co Ltd
- IVERIC bio Inc
- Sanofi SA
- Alkeus Pharmaceuticals Inc
- Astellas Pharma Inc
- Cha Biotech Co Ltd/Old
- reVision Therapeutics, Inc.
- Biogen Inc
- F Hoffmann-La Roche AG
- Ocugen Inc
Report Scope:
In this report, the Global Stargardt Disease Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Stargardt Disease Therapeutics Market, By Drug Type:
- LBS-008
- Emixustat
Stargardt Disease Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Stargardt Disease Therapeutics Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Stargardt Disease Therapeutics Market.
Available Customizations:
Global Stargardt Disease Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Stargardt Disease Therapeutics Market Outlook
- 5.1. Market Size & Forecast
- 5.1.1. By Value
- 5.2. Market Share & Forecast
- 5.2.1. By Drug Type (LBS-008, Emixustat)
- 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
- 5.3. Product Market Map
- 5.3.1. By Drug Type
- 5.3.2. By Distribution Channel
- 5.3.3. By Region
6. North America Stargardt Disease Therapeutics Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Drug Type (LBS-008, Emixustat)
- 6.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 6.2.3. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Stargardt Disease Therapeutics Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.1.1. By Value
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Drug Type
- 6.3.1.2.2. By Distribution Channel
- 6.3.1.1. Market Size & Forecast
- 6.3.2. Canada Stargardt Disease Therapeutics Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.1.1. By Value
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Drug Type
- 6.3.2.2.2. By Distribution Channel
- 6.3.2.1. Market Size & Forecast
- 6.3.3. Mexico Stargardt Disease Therapeutics Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.1.1. By Value
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Drug Type
- 6.3.3.2.2. By Distribution Channel
- 6.3.3.1. Market Size & Forecast
- 6.3.1. United States Stargardt Disease Therapeutics Market Outlook
7. Europe Stargardt Disease Therapeutics Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Drug Type (LBS-008, Emixustat)
- 7.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 7.2.3. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Stargardt Disease Therapeutics Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Drug Type
- 7.3.1.2.2. By Distribution Channel
- 7.3.1.1. Market Size & Forecast
- 7.3.2. United Kingdom Stargardt Disease Therapeutics Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Drug Type
- 7.3.2.2.2. By Distribution Channel
- 7.3.2.1. Market Size & Forecast
- 7.3.3. France Stargardt Disease Therapeutics Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Drug Type
- 7.3.3.2.2. By Distribution Channel
- 7.3.3.1. Market Size & Forecast
- 7.3.4. Italy Stargardt Disease Therapeutics Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.1.1. By Value
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Drug Type
- 7.3.4.2.2. By Distribution Channel
- 7.3.4.1. Market Size & Forecast
- 7.3.5. Spain Stargardt Disease Therapeutics Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.1.1. By Value
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Drug Type
- 7.3.5.2.2. By Distribution Channel
- 7.3.5.1. Market Size & Forecast
- 7.3.1. Germany Stargardt Disease Therapeutics Market Outlook
8. Asia-Pacific Stargardt Disease Therapeutics Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Drug Type (LBS-008, Emixustat)
- 8.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 8.2.3. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Stargardt Disease Therapeutics Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Drug Type
- 8.3.1.2.2. By Distribution Channel
- 8.3.1.1. Market Size & Forecast
- 8.3.2. Japan Stargardt Disease Therapeutics Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.1.1. By Value
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Drug Type
- 8.3.2.2.2. By Distribution Channel
- 8.3.2.1. Market Size & Forecast
- 8.3.3. India Stargardt Disease Therapeutics Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.1.1. By Value
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Drug Type
- 8.3.3.2.2. By Distribution Channel
- 8.3.3.1. Market Size & Forecast
- 8.3.4. Australia Stargardt Disease Therapeutics Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.1.1. By Value
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Drug Type
- 8.3.4.2.2. By Distribution Channel
- 8.3.4.1. Market Size & Forecast
- 8.3.5. South Korea Stargardt Disease Therapeutics Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.1.1. By Value
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Drug Type
- 8.3.5.2.2. By Distribution Channel
- 8.3.5.1. Market Size & Forecast
- 8.3.1. China Stargardt Disease Therapeutics Market Outlook
9. South America Stargardt Disease Therapeutics Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Drug Type (LBS-008, Emixustat)
- 9.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 9.2.3. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Stargardt Disease Therapeutics Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Drug Type
- 9.3.1.2.2. By Distribution Channel
- 9.3.1.1. Market Size & Forecast
- 9.3.2. Argentina Stargardt Disease Therapeutics Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Drug Type
- 9.3.2.2.2. By Distribution Channel
- 9.3.2.1. Market Size & Forecast
- 9.3.3. Colombia Stargardt Disease Therapeutics Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Drug Type
- 9.3.3.2.2. By Distribution Channel
- 9.3.3.1. Market Size & Forecast
- 9.3.1. Brazil Stargardt Disease Therapeutics Market Outlook
10. Middle East and Africa Stargardt Disease Therapeutics Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Drug Type (LBS-008, Emixustat)
- 10.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 10.2.3. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Stargardt Disease Therapeutics Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Drug Type
- 10.3.1.2.2. By Distribution Channel
- 10.3.1.1. Market Size & Forecast
- 10.3.2. Saudi Arabia Stargardt Disease Therapeutics Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Drug Type
- 10.3.2.2.2. By Distribution Channel
- 10.3.2.1. Market Size & Forecast
- 10.3.3. UAE Stargardt Disease Therapeutics Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Drug Type
- 10.3.3.2.2. By Distribution Channel
- 10.3.3.1. Market Size & Forecast
- 10.3.4. Kuwait Stargardt Disease Therapeutics Market Outlook
- 10.3.4.1. Market Size & Forecast
- 10.3.4.1.1. By Value
- 10.3.4.2. Market Share & Forecast
- 10.3.4.2.1. By Drug Type
- 10.3.4.2.2. By Distribution Channel
- 10.3.4.1. Market Size & Forecast
- 10.3.1. South Africa Stargardt Disease Therapeutics Market Outlook
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Development
- 12.2. Mergers & Acquisitions
- 12.3. Product Launches
13. Porter's Five Forces Analysis
- 13.1. Competition in the Industry
- 13.2. Potential of New Entrants
- 13.3. Power of Suppliers
- 13.4. Power of Customers
- 13.5. Threat of Substitute Products
14. Competitive Landscape
- 14.1. Kubota Pharmaceutical Holdings Co Ltd
- 14.1.1. Business Overview
- 14.1.2. Product Offerings
- 14.1.3. Recent Developments
- 14.1.4. Financials (As Reported)
- 14.1.5. Key Personnel
- 14.1.6. SWOT Analysis
- 14.2. IVERIC bio Inc
- 14.3. Sanofi SA
- 14.4. Alkeus Pharmaceuticals Inc
- 14.5. Astellas Pharma Inc
- 14.6. Cha Biotech Co Ltd/Old
- 14.7. reVision Therapeutics, Inc.
- 14.8. Biogen Inc
- 14.9. F Hoffmann-La Roche AG
- 14.10.Ocugen Inc
15. Strategic Recommendations
16. About Us & Disclaimer
